Journal: Science Advances

Article Title: Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models

doi: 10.1126/sciadv.adq0513

Figure Lengend Snippet: Examples of H&E ( A to F ), Trichrome ( G to I ), and IHC staining of muPAR ( L to Q ) and F4/80 (broad macrophage marker, R to T ) in KPC2-derived syngeneic allografts, displayed in . The black squares in (A) to (C) are shown in higher magnification in (D) to (Q). Collagen fibers, stained in blue in (G) to (I), are highlighted by white arrows, while red and yellow arrows in (L) to (N) indicate muPAR expression on stromal fibroblasts and cancer cells, respectively. Higher magnifications of the black box inserts in (L) to (N) are shown in (O) to (Q), where the spindle-shaped fibroblasts with flattened, oval nuclei can be distinguished from the round-ovoid cancer cells with large irregular nuclei and abundant cytoplasm. Brown patches in (R) to (T) indicate F4/80-positive stromal macrophages localized in matching uPAR-immunoreactive areas of the tumor sections. Scale bars, (2.5×), 1 mm; (20×) 100 μm.

Article Snippet: Last, detection was performed with the following secondary antibodies, respectively, Envision–horseradish peroxidase (HRP) anti-rabbit (Dako, #4003) for uPAR, and VisUcyte-HRP anti-mouse antibody (R&D systems, #VC005-025) for F4/80 and CD3.

Techniques: Immunohistochemistry, Marker, Derivative Assay, Staining, Expressing